These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12694518

  • 1. Prophylaxis in factor IX deficiency product and patient variation.
    Kisker CT, Eisberg A, Schwartz B, Mononine Study Group.
    Haemophilia; 2003 May; 9(3):279-84. PubMed ID: 12694518
    [Abstract] [Full Text] [Related]

  • 2. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Moret A, Caunedo P, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.
    Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA, Mononine Comparison Study Group.
    Transfusion; 2002 Feb; 42(2):190-7. PubMed ID: 11896334
    [Abstract] [Full Text] [Related]

  • 4. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J, Peynet J, Chambost H, Négrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guérois C, Caron C, Scherrmann JM, Debray M, Bridey F.
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [Abstract] [Full Text] [Related]

  • 5. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
    Hoots WK, Leissinger C, Stabler S, Schwartz BA, White G, Dasani H, Massion C, Negrier C, Schindel F, Schulman S.
    Haemophilia; 2003 Mar; 9(2):164-72. PubMed ID: 12614367
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
    Björkman S, Shapiro AD, Berntorp E.
    Haemophilia; 2001 Mar; 7(2):133-9. PubMed ID: 11260271
    [Abstract] [Full Text] [Related]

  • 7. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
    Carlsson M, Björkman S, Berntorp E.
    Haemophilia; 1998 Mar; 4(2):83-8. PubMed ID: 9873843
    [Abstract] [Full Text] [Related]

  • 8. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R.
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [Abstract] [Full Text] [Related]

  • 9. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
    Preijers T, Hazendonk HCAM, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA.
    J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
    [Abstract] [Full Text] [Related]

  • 10. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
    Lambert T, Recht M, Valentino LA, Powell JS, Udata C, Sullivan ST, Roth DA.
    Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM, Rendo P, Smith L, Altisent C.
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y, Roberts J, Bensen-Kennedy D, Jacobs I, Santagostino E, Voigt C, Feussner A, Morfini M, Sidhu J.
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
    Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA, OPTI‐CLOT study group.
    J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
    [Abstract] [Full Text] [Related]

  • 15. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G.
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB.
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.